Harvard Bioscience (HBIO) Assets (2010 - 2026)

Harvard Bioscience (HBIO) has reported Assets for 17 consecutive years, with $76.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 4.75% year-over-year to $76.3 million in Q2 2026; TTM through Jun 2026 was $76.3 million, a 4.75% decrease from a year earlier, with the FY2025 full-year figure at $80.1 million, down 36.77% from the prior year.
• Assets was $76.3 million for Q2 2026 at Harvard Bioscience, down from $77.9 million in the prior quarter.
• Over five years, Assets peaked at $158.0 million in Q1 2022 and troughed at $76.3 million in Q2 2026.
• A 5-year average of $120.2 million and a median of $132.2 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets grew 4.49% in 2022 and plunged 40.57% in 2025, its largest moves.
• Over 5 years, Assets stood at $145.4 million in 2022, then retreated by 5.5% to $137.4 million in 2023, then fell by 7.81% to $126.6 million in 2024, then slumped by 36.77% to $80.1 million in 2025, then dropped by 4.73% to $76.3 million in 2026.
• The last three Assets figures came in at $76.3 million (Q2 2026), $77.9 million (Q1 2026), and $80.1 million (Q4 2025), per Business Quant data.